<DOC>
	<DOCNO>NCT00366301</DOCNO>
	<brief_summary>The purpose study , conduct 100 center throughout United States , determine whether Lantus , long-acting insulin injection , either alone combination metformin , effective reduce C-reactive protein ( CRP ) adult type 2 diabetes . CRP marker chronic low-level inflammation , new risk factor diabetes , heart attack , stroke , cardiovascular event .</brief_summary>
	<brief_title>The LANCET Trial : A Trial Long-acting Insulin Injection Reduce C-reactive Protein Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Study Rationale Low-grade systemic inflammation indicate elevated level C-reactive protein ( CRP ) often present patient type 2 diabetes . Individuals type 2 diabetes represent vulnerable population cardiovascular event rate high among CRP reduction may greatest impact . While several class oral hypoglycemic agent show low CRP , data available new formulation long-acting insulin Lantus ( insulin glargine injection ) study comprehensively evaluate relative merit insulin-providing versus insulin-sensitizing strategy purpose . Investigational Plan This multicenter , community-based , randomize 2x2 factorial trial Lantus metformin among patient type 2 diabetes treat either diet oral monotherapy ( metformin ) poor glycemic control elevate CRP . The primary endpoint change CRP . Secondary endpoint include improvement insulin sensitivity , glycemic control , blood lipid , well select inflammatory prothrombotic marker , adipokine level . Limited data suggest short-term insulin administration patient poorly control type 2 diabetes may lower CRP , benefit CRP reduction unique insulin therapy independent glycemic control per se remain uncertain . The insulin-sensitizing agent metformin , mainstay anti-diabetic therapy , show reduce macrovascular complication among patient type 2 diabetes , randomize clinical trial , also modest CRP-lowering effect . This study design ass whether use Lantus either alone combination metformin lower CRP 14-week treatment period . Eligible men woman age 18 79 year early diabetes diet oral monotherapy baseline HbA1c 7.0-10 % CRP great equal 2.0 mg/l randomize 2X2 factorial fashion follow . First , participant assign random open-label Lantus insulin . Then , within two category , subject assign random metformin placebo . Thus , four resultant treatment group Lantus injection placebo pill , Lantus injection metformin pill , metformin pill alone , placebo pill alone . All patient receive diet exercise counseling . This study design permit test overall effect Lantus well effect combination therapy metformin CRP reduction target level glycemic control ( fingerstick fasting blood glucose &lt; 110 mg/dl ) . All participant provide glucometer fingerstick glucose test calibrated report plasma-referenced value .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Men woman age 18 79 Type 2 diabetes , treat diet oral drug metformin HbA1c great equal 7 % less equal 10 % Creactive protein great equal 2 mg/L Baseline use metformin insulin Type 1 diabetes , history ketoacidosis positive antiGAD antibody History congestive heart failure require drug therapy Active liver disease Kidney impairment Recent initiation change dose statin , fibric acid derivative , angiotensin receptor blocker , nonsteroidal antiinflammatory agent , corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>insulin</keyword>
	<keyword>insulin injection</keyword>
	<keyword>metformin</keyword>
	<keyword>C-reactive protein</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>glycemic control</keyword>
	<keyword>inflammation</keyword>
</DOC>